An interventional study of Nd:YAG laser 1064 nm in Rosacea, Erythematotelangiectatic, sponsored by Hawler Medical University. Completed at 1 site in Iraq. Open to participants aged 32 Years to 52 Years. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Hawler Medical University · Not applicable, Interventional, and Treatment
The goal of this clinical study is to assess the effectiveness of Nd:YAG laser 1064 nm in the long pulse mode in the treatment of signs of rosacea including the erythema of the face and telangiectasia. The used parameter of this laser was of very low energy (spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 millijoules (mJ) and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval) and also its was expected to have minimal adverse effects.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
This study's enrollment of 30 is below the median of 61 across 200 interventional studies indexed under Rosacea.
Browse Rosacea studies →Hawler Medical University is the lead sponsor of 59 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with rosacea received treatment with Nd:YAG laser with spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval
Device: Nd:YAG laser 1064 nm
The entire face of each patient with rosacea was treated with long-pulse 1064nm Nd:YAG laser. The parameters that been used were spot size: 5mm, fluence: 4.07 J/Cm2, energy: 800 mJ and frequency: 5 Hz. About 2-3 passes performed in each treatment session. Up to four sessions were performed for each patient with 2 weeks interval.
Changes in erythema of face of patients with rosacea been treated by ND:YAG laser 1064 nm long pulse width by using clinician erythema scale (CEA)
Erythema was graded from 0 to 4 using clinician erythema assessment scale (CEA). The score 0 is the lowest score of erythema and score 4 means the highest severity of erythema of the skin
Time frame: Three months
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Nov 2023, 7 months.
Of 42 interventional studies with no phase under Rosacea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hawler Medical University